Clinical trial with 2% sodium cromoglycate (Opticrom) in vernal keratoconjunctivitis.

Hennawi, M

doi:10.1136/bjo.64.7.483

Cited by 37 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disease has a wide geographical distribution, but it is infrequent in temperate areas and it is common in the Middle-East countries, in cluding Israel [1]. In this geographical area the disease seems to be less season-linked than pretended by its designation, and in contrast to reports from temper ate areas, it has been claimed not to be linked to sys temic allergic conditions [1,2].…”

Section: Introductionmentioning

confidence: 54%

Allergen-Specific Immunoglobulin E Antibodies in Tears and Serum of Vernal Conjunctivitis Patients

Sompolinsky

Samra²,

Zavaro

et al. 1984

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Tears and sera of 53 patients of vernal conjunctivitis were examined for antibodies of the IgE type to a panel of 18 allergens. In 18 of the patients (34.0%) allergen-specific IgE was demonstrated in both tears and serum, in 3 (5.7%) in tears only, and in 4 (7.5%) in serum only. The antigen-specific reactions with tear fluid were found in patients with the highest total IgE levels, not only in tears but also in serum. This is evidence for a specific, local allergic reaction in these patients. Most positive reactions were to perennial allergens, particularly house dust mites, cat epithelium and Bermuda grass. This fact is in harmony with the lack of season-linked symptoms in most patients in this geographical area.

show abstract

Section: Introductionmentioning

confidence: 54%

Allergen-Specific Immunoglobulin E Antibodies in Tears and Serum of Vernal Conjunctivitis Patients

Sompolinsky

Samra²,

Zavaro

et al. 1984

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Topical corticosteroids are the most effective treatment for moderate to severe forms of VKC because of their broad and early interference with the inflammatory cascade. Sodium cromoglycate, a non-toxic mast cell stabiliser with anti-inflammatory activity has proved effective in the treatment of VKC 7,8 . Bulbar form of the disease was found to be sensitive to sodium cromoglycate alone.…”

Section: Discussionmentioning

confidence: 99%

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Nagrale¹

2017

jmscr

View full text Add to dashboard Cite

“…Mast cell stabilisers such as cromolyn sodium, nedocromil sodium, lodoxamide and pemirolast interfere with the release of mast cell mediators by blocking calcium transport across the mast cell membrane requiring prophylactic treatment or a loading period 71. Although mast cell stabilisers are unanimously effective in studies in Europe and North America, results from the Middle East and Africa have not consistently shown a benefit 3 9 16 31 71–73…”

Section: Treatmentmentioning

confidence: 99%

Vernal keratoconjunctivitis: an update

Smedt¹,

2012

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterised by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae. Although rare in temperate regions, it represents an important cause of hospital referral in many parts of Africa and Asia. Clinical and immunohistochemical studies suggest that IgE-dependent (type I allergic) and IgE-independent (type IV allergic) mechanisms are involved in the immunopathogenesis of VKC, in which various inflammatory cells, including different T cell subpopulations play an active role via a cascade of chemical mediators. Endocrine, genetic, neurogenic, environmental and socioeconomic risk factors have been identified. However, its aetiology and pathophysiology remain unclear. The clinical course of this disease is usually benign and self-limiting, but a minority of patients will face very debilitating and sight threatening complications. Topical corticosteroids are often used during flare-ups in combination with mast cell stabilizers as maintenance treatment for VKC. However this management is unsatisfactory in controlling severe cases and avoiding recurrences. Non-steroidal immune modulators such as ciclosporin A and tacrolimus are promising alternatives, but tolerance to these agents needs to be improved and production costs reduced. The purpose of this review is to give an update on its epidemiology, immunopathogenesis and management. EPIDEMIOLOGYVernal keratoconjunctivitis (VKC) is a bilateral, chronic, external ocular inflammatory disorder, mainly affecting patients in their first or second decade.1-3 Although it is a rare allergic disorder in temperate regions, in many parts of Africa, Latin America and Asia VKC represents an important cause for hospital attendance, ranging from 3% to 6% of patients of all ages, rising to 33% and 90% in children and adolescents.2 4-7 A population prevalence of 4% to 5% has been found among African children.3 8 In large European and Asian case series boys appear to be affected more than girls, but this sex distribution is not found uniformly in Africa, and becomes less obvious with age.

show abstract

Clinical trial with 2% sodium cromoglycate (Opticrom) in vernal keratoconjunctivitis.

Cited by 37 publications

References 7 publications

Allergen-Specific Immunoglobulin E Antibodies in Tears and Serum of Vernal Conjunctivitis Patients

Allergen-Specific Immunoglobulin E Antibodies in Tears and Serum of Vernal Conjunctivitis Patients

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Vernal keratoconjunctivitis: an update

Contact Info

Product

Resources

About